| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2001; 40: 205-211
© 2001 British Society for Rheumatology
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
University College London Centre for Rheumatology, London, UK
Objectives. An open study of B-lymphocyte depletion was undertaken in rheumatoid arthritis (RA) patients to test the hypothesis that B lymphocytes may be essential to disease perpetuation.
Methods. Five patients with refractory RA were treated with a monoclonal anti-CD20 antibody, cyclophosphamide and prednisolone and followed for 12–17 months. Patient 2 received further treatments at 8 and 12 months and patient 4 at 11 months.
Results. At 26 weeks all patients satisfied the American College of Rheumatology ACR50 and patients 1–3 the ACR70 criteria of improvement, without further therapy. Patients 1, 3 and 5 achieved ACR70 at 1 yr and rheumatoid factor (RF) levels fell to normal. In patients 3 and 5, B lymphocytes returned without relapse. Patient 2 relapsed at 28 weeks and patient 4 at 38 weeks, coincident with the return of B lymphocytes in the presence of raised RF levels. Both achieved ACR70 on retreatment. Adverse events were limited to respiratory episodes (two patients) and marginal thrombocytopenia (one patient).
Conclusions. These findings are consistent with the concept that RA is critically dependent on B lymphocytes and suggest that B-lymphocyte depletion may be a safe and effective therapy.
KEY WORDS: B lymphocyte, Anti-CD20, Rituximab, Autoimmunity, Rheumatoid arthritis.
Correspondence to: J. C. W. Edwards, Rheumatology, Arthur Stanley House, 40–50 Tottenham Street, London W1P 9PG, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D E Furst, E C Keystone, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, J Braun, B Bresnihan, G R Burmester, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 Ann Rheum Dis, January 1, 2010; 69(Suppl_1): i2 - i29. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kishi, T. Nanki, K. Watanabe, A. Takamura, and N. Miyasaka A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus Rheumatology, April 1, 2009; 48(4): 447 - 448. [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii2 - iii25. [Full Text] [PDF]
|
|
|
|
|
|
Y. Tamimoto, T. Horiuchi, H. Tsukamoto, J. Otsuka, H. Mitoma, Y. Kimoto, H. Nakashima, K. Muta, Y. Abe, C. Kiyohara, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines Rheumatology, June 1, 2008; 47(6): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Boross, P. L. van Lent, J. Martin-Ramirez, J. van der Kaa, M. H. C. M. Mulder, J. W. C. Claassens, W. B. van den Berg, V. L. Arandhara, and J. S. Verbeek Destructive Arthritis in the Absence of Both Fc{gamma}RI and Fc{gamma}RIII J. Immunol., April 1, 2008; 180(7): 5083 - 5091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McGonagle, A. L. Tan, J. Madden, A. C. Rawstron, A. Rehman, P. Emery, and S. Thomas Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab Rheumatology, April 1, 2008; 47(4): 552 - 553. [Full Text] [PDF]
|
|
|
|
|
|
A Kavanaugh, S Rosengren, S J Lee, D Hammaker, G S Firestein, K Kalunian, N Wei, and D L Boyle Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results Ann Rheum Dis, March 1, 2008; 67(3): 402 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. DiLillo, Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice J. Immunol., January 1, 2008; 180(1): 361 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-D. Bouaziz, K. Yanaba, G. M. Venturi, Y. Wang, R. M. Tisch, J. C. Poe, and T. F. Tedder Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice PNAS, December 26, 2007; 104(52): 20878 - 20883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. O'Neill, Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas, and A. Finnegan Expression of CD80/86 on B Cells Is Essential for Autoreactive T Cell Activation and the Development of Arthritis J. Immunol., October 15, 2007; 179(8): 5109 - 5116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Breedveld, S. Agarwal, M. Yin, S. Ren, N. F. Li, T. M. Shaw, and B. E. Davies Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response J. Clin. Pharmacol., September 1, 2007; 47(9): 1119 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. W. Edwards, G. Cambridge, and M. J. Leandro Repeated B-cell depletion in clinical practice Rheumatology, September 1, 2007; 46(9): 1509 - 1509. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Isenberg 30 million, around 10 000 ... and 18 ... Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service Rheumatology, August 1, 2007; 46(8): 1219 - 1220. [Full Text] [PDF]
|
|
|
|
|
|
C. Popa, M. J. Leandro, G. Cambridge, and J. C. W. Edwards Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs Rheumatology, April 1, 2007; 46(4): 626 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Winchester A Golden Anniversary: Recognition That Rheumatoid Arthritis Sera Contain Autoantibodies Specific for Determinants on Native IgG Molecules J. Immunol., February 1, 2007; 178(3): 1227 - 1228. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Leandro, N. Cooper, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology, January 1, 2007; 46(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Cordeiro and D A Isenberg Treatment of inflammatory myopathies. Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hamaguchi, Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder Antibody isotype-specific engagement of Fc{gamma} receptors regulates B lymphocyte depletion during CD20 immunotherapy J. Exp. Med., March 20, 2006; 203(3): 743 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M Summers and D. R Kockler Rituximab Treatment of Refractory Rheumatoid Arthritis Ann. Pharmacother., December 1, 2005; 39(12): 2091 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Leandro, G. Cambridge, J. C. Edwards, M. R. Ehrenstein, and D. A. Isenberg B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology, December 1, 2005; 44(12): 1542 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease PNAS, October 18, 2005; 102(42): 15178 - 15183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doan and E. Massarotti Rheumatoid Arthritis: An Overview of New and Emerging Therapies J. Clin. Pharmacol., July 1, 2005; 45(7): 751 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. O'Neill, M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan Antigen-Specific B Cells Are Required as APCs and Autoantibody-Producing Cells for Induction of Severe Autoimmune Arthritis J. Immunol., March 15, 2005; 174(6): 3781 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Chambers and D Isenberg Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases Lupus, March 1, 2005; 14(3): 210 - 214. [Abstract] [PDF]
|
|
|
|
|
|
J. C. W. Edwards and G. Cambridge Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology, February 1, 2005; 44(2): 151 - 156. [Full Text] [PDF]
|
|
|
|
|
|
C Gorman, M Leandro, and D Isenberg Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Lupus, May 1, 2004; 13(5): 312 - 316. [Abstract] [PDF]
|
|
|
|
|
|
K. Tanaka, T. Yamamoto, Y. Aikawa, K. Kizawa, K. Muramoto, H. Matsuno, and A. Muraguchi Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice Rheumatology, November 1, 2003; 42(11): 1365 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G P Fra, G C Avanzi, and E Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus, October 1, 2003; 12(10): 783 - 787. [Abstract] [PDF]
|
|
|
|
|
|
I. B. McInnes, B. P. Leung, M. Harnett, J. A. Gracie, F. Y. Liew, and W. Harnett A Novel Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived Phosphorylcholine-Containing Glycoprotein ES-62 J. Immunol., August 15, 2003; 171(4): 2127 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ruggenenti, C. Chiurchiu, V. Brusegan, M. Abbate, A. Perna, C. Filippi, and G. Remuzzi Rituximab in Idiopathic Membranous Nephropathy: A One-Year Prospective Study J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1851 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zecca, B. Nobili, U. Ramenghi, S. Perrotta, G. Amendola, P. Rosito, M. Jankovic, P. Pierani, P. De Stefano, M. R. Bonora, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood, May 15, 2003; 101(10): 3857 - 3861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J Looney Treating human autoimmune disease by depleting B cells Ann Rheum Dis, October 1, 2002; 61(10): 863 - 866. [Full Text] [PDF]
|
|
|
|
|
|
M J Leandro, J C W Edwards, and G Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis, October 1, 2002; 61(10): 883 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Arzoo, S Sadeghi, and H A Liebman Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) Ann Rheum Dis, October 1, 2002; 61(10): 922 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Nielsen and R. G. Q. Leslie Complement's participation in acquired immunity J. Leukoc. Biol., August 1, 2002; 72(2): 249 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takemura, P. A. Klimiuk, A. Braun, J. J. Goronzy, and C. M. Weyand T Cell Activation in Rheumatoid Synovium Is B Cell Dependent J. Immunol., October 15, 2001; 167(8): 4710 - 4718. [Abstract] [Full Text] [PDF]
|
|